Nippon India Pharma Fund - Growth
Medium
Risk
Equity
Other
+
20.01
%
20.01
%
3Y annualised
+
0.26
%
0.26
%
1D
1M
6M
1Y
3Y
All
Fund size
7132
NAV:
Mar 7, 2024
428.392
Sector
Tech
Type
Equity
Launched
Jun 2004
Min Investment
5000
Expense Ratio
2
Risk
Medium
Portfolio allocation
Top 10 Holdings
% Value
Sun Pharmaceuticals Industries Ltd
14.51
%
Lupin Ltd
8.42
%
Cipla Ltd
6.43
%
Apollo Hospitals Enterprise Ltd
5.55
%
Dr Reddy's Laboratories Ltd
4.95
%
Divi's Laboratories Ltd
4.41
%
Gland Pharma Ltd
4.21
%
Zydus Lifesciences Ltd
3.96
%
Abbott India Ltd
3.44
%
J.B. Chemicals & Pharmaceuticals Ltd
3.26
%
Expense ratio, exit load and tax
Expense Ratio:
2
%
Inclusive of GST
Exit load
Exit load of 1.0% if redeemed within 1.0 Months, 0.0 % if redeemed after 1.0 Months.
Tax implication
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
Fund house & investment objective
Nippon India Pharma Fund - Growth
More details
Investment objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Scheme Information Document
Mutual Fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not an indicator of future returns.
Calculate returns
One-time
Monthly SIP
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
* Returns are calculated as per lifetime average per annum returns of the fund.
Calculate returns
Monthly SIP
One-time
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
